University College London Cancer Institute, London, United Kingdom
Jonathan A. Ledermann , Alain Lortholary , Richard T. Penson , Emma Gibbs , Diane M. Provencher , Ilan Bruchim , Tomas Huzarski , Maria Pilar Barretina-Ginesta , Roberto Sabbatini , Linda R. Mileshkin , Nicoletta Colombo , Tjoung-Won Park-Simon , Koji Matsumoto , Gabe S. Sonke , Olga N. Mikheeva , Jae-Weon Kim , Gustavo Colagiovanni Girotto , Hannelore Denys , Elizabeth S. Lowe , Eric Pujade-Lauraine
Background: In the SOLO2 trial (ENGOT Ov-21; NCT01874353), maintenance therapy with the PARP inhibitor olaparib significantly improved PFS vs placebo (PBO) in BRCAm PSR SOC pts (HR 0.30, 95% CI 0.22–0.41, P<0.0001; median 19.1 vs 5.5 months) and was well tolerated (Pujade-Lauraine et al, SGO 2017). We analyzed AEs in SOLO2, the first study in PSR SOC to use the olaparib tablet formulation. Methods: Pts with BRCAm PSR SOC, who were in response to platinum chemotherapy, were treated with olaparib (300 mg bid; tablets; n=195) or PBO (n=99) until progression. AEs were graded by CTCAE v4.0. Results: The most common AEs with olaparib – nausea, fatigue/asthenia, anemia, and vomiting – were largely grade 1–2, though anemia was the most common grade ≥3 AE. AEs of fatigue/asthenia, vomiting and nausea generally improved as treatment continued, though fatigue/asthenia and anemia could last for several months (table). Most AEs were manageable by supportive treatment, dose interruptions (olaparib, 45%; PBO, 18%) and dose reductions (olaparib, 25%; PBO, 3%). Discontinuation of olaparib due to AEs was minimal (11%); anemia and neutropenia were the only AEs leading to discontinuation of olaparib in >one pt. Conclusions: Most AEs experienced by pts receiving olaparib tablets in SOLO2 were low grade and manageable. Initial nausea, vomiting and fatigue generally improved with ongoing treatment. The majority of AEs first occurred within the first three months of treatment. AEs causing treatment discontinuation were rare and mainly hematological. Clinical trial information: NCT01874353
Nausea | Vomiting | Fatigue/asthenia | Anemia | Neutropenia | ||||||
---|---|---|---|---|---|---|---|---|---|---|
O | P | O | P | O | P | O | P | O | P | |
Pts with AE | 148 (80) | 33 (33) | 73 (37) | 19 (19) | 128 (66) | 39 (39) | 85 (44) | 8 (8) | 38 (20) | 6 (6) |
Grade 3–4 | 5 (3) | 0 | 5 (3) | 1 (1) | 8 (4) | 2 (2) | 38 (19) | 2 (2) | 10 (5) | 4 (4) |
First onset in 0-3 months | 138 (71) | 27 (27) | 48 (25) | 10 (10) | 106 (54) | 26 (26) | 58 (30) | 5 (5) | 20 (10) | 5 (5) |
Median duration of first event, months* | 1.72 | 0.43 | 0.07 | 0.07 | 5.78 | 2.04 | 2.79 | 2.60 | 0.95 | 0.69 |
Supportive treatment | 79 (41) | 9 (9) | 17 (9) | 7 (7) | 7 (4) | 1 (1) | 34 (17) | 1 (1) | 5 (3) | 2 (2) |
Discontinuation | 1 (1) | 0 | 0 | 0 | 0 | 0 | 6 (3) | 0 | 3 (2) | 0 |
Values are n (%) unless otherwise stated; *Only uses AEs with a resolution date, n<total sample size; O, olaparib; P, PBO
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2020 ASCO Virtual Scientific Program
First Author: Joyce F. Liu
2020 ASCO Virtual Scientific Program
First Author: Andres Poveda
2023 ASCO Annual Meeting
First Author: Philipp Harter
2022 ASCO Annual Meeting
First Author: Sandro Pignata